Canyon Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Canyon Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-494,194	Closed	-$36.4M	–	54
2016 Q4	$36.4M	Sell	494,194 -209	-0%	-$17K	1.22%	19
2016 Q3	$43.1M	Buy	494,403 +109,018	+28%	+$10.3M	1.57%	14
2016 Q2	$33.2M	Sell	385,385 -2,283	-0.6%	-$197K	1.32%	16
2016 Q1	$30.8M	Sell	387,668 -20,113	-5%	-$1.82M	1.23%	22
2015 Q4	$51.3M	Sell	407,781 -323	-0.1%	-$39K	1.58%	21
2015 Q3	$42.5M	Buy	408,104 +40,981	+11%	+$5.26M	1.17%	26
2015 Q2	$45.3M	Buy	+367,123	New	+$46.3M	1.2%	26

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Canyon Capital Advisors's VRTX Position: Q1 2017 in Review

Canyon Capital Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2017, closing a stake of 494,194 shares — an estimated $36.4M sold.

Canyon Capital Advisors first reported a position in VRTX in Q2 2015 and held it in 7 quarters. The position peaked at $51.3M in Q4 2015. 522 funds tracked by Wall St. Rank hold VRTX as of Q1 2017.

Canyon Capital Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Canyon Capital Advisors sold 494,194 Vertex Pharmaceuticals shares in Q1 2017, an estimated $36.4M.
Canyon Capital Advisors first reported a position in Vertex Pharmaceuticals in Q2 2015 and held it in 7 quarters.
Canyon Capital Advisors's Vertex Pharmaceuticals position peaked at $51.3M in Q4 2015.
522 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2017.

Based on Canyon Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.